Ligand currently has multiple unpartnered programs available for out-licensing in addition to our Captisol, OmniAb, LTP and HepDirect technologies which are available to partners that could benefit from formulation, antibody discovery or other early stage drug targeting and development expertise.
Granulocyte colony stimulating factor (GCSF) acts on its receptor to stimulate the differentiation of bone marrow hematopoietic cells to form neutrophils.
Ligand is developing a novel Captisol® formulation of Busulfan for use as a conditioning agent prior to hematopoietic stem cell transplantation.
Captisol-enabled® Sertraline (LGD-953) is designed to be the potential first aqueous oral solution to meet the growing demand for better liquid antidepressants for elderly and pediatric patients who are the least able to ingest pills.
Ligand is developing a Captisol-enabled™ injectable formulation of the antihistamine cetirizine to provide rapid onset to treat acute, life-threatening, allergy symptoms.
Ligand is developing novel Captisol-enabled™ silymarin composition for application in the topical sun damage and anti‐aging premium skin-care markets.
FMS-like tyrosine kinase-3 (FLT3) is a receptor tyrosine kinase with an important role in hematopoietic progenitor cell development.
Glucokinase (GKA) is an enzyme that facilitates removal of glucose in circulation and functions as a glucose sensor mainly in the liver and pancreas cells.
Chemokine receptor 1 (CCR1) is a receptor on the surface of various immune cells (e.g. monocytes and T-cells) that bind multiple chemokines and directly mediates inflammatory responses through leukocyte chemotaxis and cytokine balance.
The voltage-gated sodium channel Nav1.9 is primarily expressed in nociceptive and myenteric neurons and plays a key role in the transmission and regulation of pain sensation. Modulation of Nav1.9 function represents a novel pain drug discovery strategy that should avoid the limitations of opioid based pain therapies.
The Branched Chain Amino Acid Transferase (BCAT2) enzyme is expressed in mitochondria and is responsible for the initial step in the metabolism branched chain amino acid (BCAA) such as valine, leucine and isoleucine. Aberrant levels of BCAA metabolites are implicated in the development of cardiometabolic diseases as well as diseases caused by inborn errors of metabolism.
Cyclic GMP-AMP synthase (cGAS) is a cytosolic double-stranded DNA sensor that activates a Type I interferon response. cGAS is a component of the innate immune system protecting against DNA viral infection as well as certain retroviruses. Aberrant cGAS activity can lead to autoimmune disorders as well as rare neurodevelopmental encephalopathies.
Glycogen Synthase is a key enzyme in the glycogenesis pathway and produces glycogen, a key cellular fuel in humans. Deficits in glycogen clearance lead to several disorders including inborn errors of metabolism such as Pompe disease.
The neuronal voltage-gated sodium channel Nav1.1 plays an important role in regulating central nervous system excitability. Loss of function mutations of the human Nav1.1 gene leads to increased neuronal excitability which results in debilitating seizure disorders such as Dravet Syndrome and Generalized Epilepsy with Febrile Seizures Plus.
ApoL1 is a protein involved in the innate immune system providing protection from trypanosome infections leading to African Sleeping Sickness. Genetic variants of ApoL1 that provide enhanced trypanosome immunity have been linked to a significantly increased risk of developing Chronic Kidney Disease and End Stage Renal Disease in African populations and populations with recent African ancestry, including African Americans.
